Small ALS trial found no significant disease-progression difference
A phase II, randomised, placebo-controlled, double-blind trial of cannabis extract for amyotrophic lateral sclerosis: the EMERALD trial.
AI Summary
The EMERALD trial asked whether a cannabis-based medicine extract could affect disease progression in people with amyotrophic lateral sclerosis (ALS). In this randomised, double-blind, placebo-controlled trial, 17 participants were assigned to extract or placebo for 6 months, but only 8 completed treatment. The primary outcome, the ALS Functional Rating Scale-Revised score at treatment end, did not differ significantly between groups; the trial also found no significant differences in its secondary outcomes.
Exploratory analyses suggested possible effects on pain and cognition, including a statistically significant executive-function result, but the other reported pain and memory comparisons were not statistically significant. These small-sample findings are tentative and need confirmation. Because recruitment fell short of the target and the study was underpowered, this abstract cannot establish whether the extract slows ALS progression or reliably improves symptoms; this is an abstract-based summary.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Neuroprotection research papers you might find interesting.
Preclinical review finds CBD effects on nitric oxide vary by enzyme
Pilot study finds greater stress and dementia risk indicators in men
Review explores dual-action CB2 ligands for neurological disorders
Explore More Research
Stay informed about the latest cannabis science.